Prospective randomized study evaluating the efficacy of the spherical adsorptive carbon AST-120 in chronic kidney...

Area of Science:

• Nephrology
• Pharmacology

Background:

• Chronic kidney disease (CKD) affects millions globally, characterized by progressive loss of renal function.
• Managing CKD progression, especially in patients with moderate renal impairment, is a significant clinical challenge.

Purpose of the Study:

• To evaluate the efficacy of AST-120, a spherical adsorptive carbon agent, when added to conventional treatments for inhibiting CKD progression.
• To assess the impact of AST-120 on the rate of decline in glomerular filtration rate (GFR) in CKD patients with moderate renal dysfunction.

Main Methods:

• A randomized controlled trial involving 43 CKD patients with GFR between 20-70 ml/min.
• Patients were randomized into a control group (conventional treatment only) and an AST-120 group (conventional treatment plus AST-120) for a 1-year intervention period.
• The primary outcome measure was the change in GFR over the intervention period.

Main Results:

• While mean monthly GFR changes (DeltaGFR) did not differ significantly between groups during the intervention, a detailed analysis revealed significant findings.
• The rate of GFR decline was significantly retarded (p < 0.001) in the AST-120 group compared to their baseline observation period.
• No significant change in the rate of GFR decline was observed in the control group.

Conclusions:

• Co-administration of AST-120 with conventional treatments effectively retards the decline in renal function in CKD patients with moderate renal impairment.
• AST-120 represents a potential therapeutic strategy for slowing CKD progression and preserving kidney function.